: iStockAnalyst.com Symbols Feed

Microchip Tech (NASDAQ:MCHP) Downgraded To Sell At Goldman Sachs

Wed, 05 Nov 2008 12:47:00 GMT

Goldman Sachs is out with a interesting downgrade to Sell on Microchip Tech (NASDAQ:MCHP) noting their checks indicate the market is starting to shift away from its core strengths, leading them to reevaluate the story. Firm says they have done extensive field work on the microcontroller market, prompted in part by Microchip’s proposal on October 2, 2008, to acquire Atmel’s MCU business. They have conducted more than a dozen meetings and calls with industry participants and contacts. They also spent two full days at the Embedded Systems conference in Boston on October 27-28, meeting with dozens of companies in the MCU ecosystem to garner insight into the state of the market. The slowdown in Microchip’s core growth and impact from increasing competition in MCUs is at the center of the downgrade to Sell from Neutral as well as a reduction in estimates and price target.[More...]

Area Gets First-of-Its-Kind in State Communication Tower

Wed, 15 Jul 2009 19:48:00 GMT

Jul. 15--It's designed to provide communications for emergency responders whenever and wherever they need it in a seven-county area of northwestern Pennsylvania.
The first of its kind in Pennsylvania, a state-of-the-art mobile communications unit complete with 65-foot tower is now available for use in Crawford, Clarion, Erie, Forest, Mercer, Venango and Warren counties.
The communications equipment was acquired from Mobilcom of Meadville while the specialized trailer was constructed by Pepro Corp. of Oil City.

[More...]

Medicure Announces Intention to Delist From the American Stock Exchange

Wed, 18 Jun 2008 18:51:00 GMT

- Medicure Inc. today announced that its Board of Directors has unanimously decided to submit a written notice to the American Stock Exchange of its intention to file a Form 25 with the United States Securities and Exchange Commission in order to voluntarily delist its common shares from Amex.[More...]

Medicure Announces Intention to Delist From the American Stock Exchange

Wed, 18 Jun 2008 18:50:00 GMT

Medicure Inc. today announced that its Board of Directors has unanimously decided to submit a written notice to the American Stock Exchange of its intention to file a Form 25 with the United States Securities and Exchange Commission in order to voluntarily delist its common shares from Amex.[More...]

Medicure Announces Appointment of New CFO

Wed, 11 Jun 2008 11:56:00 GMT

Medicure Inc. , a cardiovascular-focused biopharmaceutical company, today announced the appointment of Dwayne Henley as its new Chief Financial Officer. Mr. Henley is a Chartered Accountant with nearly 10 years of senior management and finance experience in both public and private companies. Mr. Henley will replace, Derek Reimer, who has resigned to pursue other interests.[More...]

Medicure Announces Appointment of New CFO

Wed, 11 Jun 2008 11:56:00 GMT

- Medicure Inc. , a cardiovascular-focused biopharmaceutical company, today announced the appointment of Dwayne Henley as its new Chief Financial Officer. Mr. Henley is a Chartered Accountant with nearly 10 years of senior management and finance experience in both public and private companies. Mr. Henley will replace, Derek Reimer, who has resigned to pursue other interests.[More...]

Medicure Receives Notice From the American Stock Exchange - CCN

Fri, 30 May 2008 20:56:00 GMT

- Medicure Inc. , a cardiovascular-focused biopharmaceutical company, today announced it received a letter from the American Stock Exchange stating that the Amex has determined that Medicure is not in compliance with certain continued listing standards, as set forth in Part 10 of the Amex Company Guide , and therefore has become subject to the procedures and requirements of Section 1009 of the Company Guide.[More...]

Medicure Receives Notice From the American Stock Exchange - Market Wire - Jun 1 2008 4:28AM

Fri, 30 May 2008 20:55:00 GMT

Medicure Inc. , a cardiovascular-focused biopharmaceutical company, today announced it received a letter from the American Stock Exchange stating that the Amex has determined that Medicure is not in compliance with certain continued listing standards, as set forth in Part 10 of the Amex Company Guide , and therefore has become subject to the procedures and requirements of Section 1009 of the Company Guide.[More...]

BellwetherReport.com Initiates Analyst Coverage on LNG, MCU, GSS and VTG

Wed, 16 Apr 2008 18:20:00 GMT

BellwetherReport.com is the leading online financial newsletter for investors seeking top independent and unbiased research. Investors seeking free and unbiased analyst opinions on the companies mentioned in this release are encouraged to sign up to www.bellwetherreport.com for a free subscription to access these reports. Today, we have scheduled interviews with a number of the top analysts in North America to speak with them in regards to the current market activity and position of Cheniere Energy Inc. , Medicure Inc , Golden Star Resources Ltd. and Vantage Energy Services Inc. .[More...]

Medicure Announces Presentation of Phase II Matched Results at Cardiovascular Conference

Wed, 16 Apr 2008 10:56:00 GMT

Medicure Inc. , a cardiovascular-focused biopharmaceutical company, today announced that the positive results from the Phase II MATCHED study, which evaluated the combination of MC-1 and lisinopril in patients with coexisting type II diabetes and hypertension, will be presented today at the Arteriosclerosis, Thrombosis and Vascular Biology Annual Conference 2008 in Atlanta, GA.[More...]

Medicure Announces Third Quarter Fiscal 2008 Financial Results

Mon, 14 Apr 2008 20:10:00 GMT

Medicure Inc. , a cardiovascular-focused biopharmaceutical company, today reported the results of operations for the three and nine month periods ended February 29, 2008. All amounts referenced herein are in Canadian dollars unless otherwise noted. At the close of business on February 29, 2008, the exchange rate was CAD$1.00 equals US$1.02.[More...]

Medicure Comments on Positive AGGRASTAT Results Presented at the American College of Cardiology Annual Scientific Session

Thu, 03 Apr 2008 19:55:00 GMT

Medicure Inc. , a cardiovascular-focused biopharmaceutical company, today commented on the positive results of two large AGGRASTAT® studies, MULTI-STRATEGY 2 and ON-TIME 2, that were presented at the Late Breaking Sessions of the American College of Cardiology 57th Annual Scientific Session.[More...]